智通财经APP讯,中科生物(01237)发布公告,集团预期截至2025年12月31日止财政年度将取得股东应占溢利约4400万港元,而2024年度的股东应占溢利约为300万港元,主要由于(i)本财政年度确认汇兑收益净额约人民币1270万元,而上一年度则确认汇兑亏损净额人民币2180万元;(ii) 本财政年度的银行利息收入增加约人民币2400万元。
智通财经APP讯,中科生物(01237)发布公告,集团预期截至2025年12月31日止财政年度将取得股东应占溢利约4400万港元,而2024年度的股东应占溢利约为300万港元,主要由于(i)本财政年度确认汇兑收益净额约人民币1270万元,而上一年度则确认汇兑亏损净额人民币2180万元;(ii) 本财政年度的银行利息收入增加约人民币2400万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.